AC Immune AG (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on the discovery and development of therapies for Alzheimer’s disease and other neurodegenerative disorders. The company leverages two proprietary technology platforms—Morphomer™ for small-molecule therapies and SupraAntigen™ for antibody and vaccine development—to target misfolded proteins implicated in conditions such as Alzheimer’s, Parkinson’s and Creutzfeldt-Jakob disease.
The firm’s pipeline includes multiple clinical-stage assets designed to address both amyloid-beta and tau pathologies. Lead programs include antibody candidates in collaboration with global partners and a proprietary tau vaccine in Phase 2 development. Preclinical efforts extend to novel small molecules aimed at inhibiting toxic protein aggregation, with the goal of modifying disease progression rather than solely treating symptoms.
Since its founding in 2003, AC Immune has established collaborations with major biopharma companies to co-develop and commercialize its therapeutic candidates. The company maintains research facilities in Switzerland and the United States, enabling seamless integration of discovery, translational and clinical activities across geographies. Partnerships have provided access to complementary expertise, regulatory support and global development networks.
AC Immune is led by a management team of seasoned industry professionals, spearheaded by co-founder and Chief Executive Officer Andrea Pfeifer. The board of directors and scientific advisory panels bring extensive experience in neuroscience, drug development and regulatory affairs. Through its dual‐platform approach, AC Immune aims to deliver novel treatments that can alter the course of devastating neurodegenerative diseases.
AI Generated. May Contain Errors.
